Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 801–874 of 874
Effects of Sacituzumab on Breast Cancer: Target Therapy
Khatibi, E. A., Gholikhani, T., Brito, B. J., & Moghimi, N. F. (2023) · Biomedical Research Bulletin · doi:10.34172/biomedrb.2023.27
“…lung, colorectal, and TNBC. 35,43 Sacituzumab’s pharmacokinetics, SN-38, IgG, and hRS7 IgG, were evaluated in some patients who participated in the Phase II section and received 9 mg/kg and 11 mg/kg. 45,46 During the clinical study, the conjugate received 50% of the SN-38 payload every 24 hours.”
BackgroundInfluentialImmunotherapy in Breast Cancer: Situation and Challenge
Kang, Y. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202455305031
Barroso‐Sousa, R., Weis, L. N., & Tolaney, S. M. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_40
Self-citationTan, C.-F., Han, J., Zeng, B., Xiang, Z., Zeng, Y., Wang, J., Wei, X., Dai, Z., Xu, N.-Y., Xiong, W., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107931
RetractedMedikamentöse Tumortherapie jenseits der Zulassung: Molekulares Tumorboard und „Off-label-Therapie“
Steinacker, V. C., Müller-Richter, U. D. A., Hartmann, S., & Kasper, S. (2024) · Die MKG-Chirurgie · doi:10.1007/s12285-024-00499-5
Gong, X., Gu, L., Yang, D., He, Y., Li, Q., Qin, H., & Wang, Y. (2024) · eLife · doi:10.7554/elife.100923.1
Current approaches to the management of neuroendocrine breast carcinoma (NEBC): a review
Ali, M. S. (2024) · Asia-Pacific Journal of Oncology · doi:10.32948/ajo.2024.11.25
Temas Selectos en Oncología Tomo 3
Rodríguez, G. N. P., Vargas, C. A. F., & Soledispa, J. I. V. (2025) · doi:10.56470/978-9942-695-38-3
Current update on pharmacological strategies of penile cancer
Deshmukh, S. S., Chaudhari, K. S., Basu, A., & Sonpavde, G. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2492335
“…cancer and showed efficacy in metastatic urothelial carcinoma who were previous administered chemotherapy and immune checkpoint inhibitor therapy [82,83], In the phase 2 trial [NCT06161532] also known as ‘SMART’ study, Sacituzumab Govitecan is currently used with or without Atezolizumab, PD-L1…”
Table S2 from The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
Tolaney, S. M., Cardillo, T. M., Chou, C.-C., Dornan, C., & Faris, M. (2025) · doi:10.1158/1078-0432.29052886
Self-citationSchäffler, H., Jakob, D., Huesmann, S. T., Pfister, K., Veselinovic, K., Schochter, F., Leinert, E., Fink, V., Rack, B. K., Englisch, A., et al. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2510-1821
Marquez, J., Dong, J., Yue, B., Hayashi, J., Dong, C., Oshimura, M., & Serrero, G. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70665
Current Advances in Triple-Negative Breast Cancer (TNBC) Chemotherapy: A Literature Review
Murwanti, R., Rommy, & Nugroho, A. E. (2025) · Indonesian Journal of Pharmacology and Therapy · doi:10.22146/ijpther.11403
Li, W., Kang, K., Zhang, Y., Zhao, X.-X., Zhu, X., Tang, J., Li, Y., Fu, H., Yao, Q., Wang, L., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01647-y · Cited by 1
Peng, Y., Yang, C., Dong, L., Sun, X., Zheng, W., Gong, Y., Shi, Q., Ping, J., Chen, S., Zhang, W., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0752
Understanding the molecular landscape of triple-negative breast cancer
Nazir, I., Garg, A., Singh, S. K., & Kothawade, S. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33565-5.00010-4
Advanced strategies for targeting severe triple-negative breast cancer
Murari, K., Singla, N., Mishra, R., Bhat, A. A., Thapa, R., Patel, N. K., Singh, S. K., Dua, K., & Gupta, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33349-1.00007-7
Additional file 1 of Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L., George, S. H. L., & Badal, S. (2022) · Figshare · doi:10.6084/m9.figshare.20444349
Additional file 2 of Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L., George, S. H. L., & Badal, S. (2022) · Figshare · doi:10.6084/m9.figshare.20444352
Jeon, Y., Jo, U., Hong, J., Gong, G., & Lee, H. J. (2022) · Figshare · doi:10.6084/m9.figshare.21206590
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Yang, Q., Li, B., Chen, Y., & Yang, H. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.01.002
Regulation of the HCK-GS-HIF1α axis, a promising druggable target for aggressive TNBC
Capiz, A. P., & García‐González, V. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.012
Henderson, B. D., Mcmahon, L., Lewis, F., Marion, C., Hurley, S. M., Narinda, I., Kanjuga, M., Norris, L. A., Martin, C. M., Conlon, N. T., et al. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100459
RetractedFuture directions and challenges in cancer pharmacology
Kshirsagar, A. D., Singh, M. N., Bhaumik, A., & Wal, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00020-0
MODERN APPROACHES TO THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
Melekhov, S., Kononchuk, V., Khristin, A., Sidorov, S., Gulyaeva, L. F., & Kushlinskii, N. E. (2026) · Problems of Biological Medical and Pharmaceutical Chemistry · doi:10.29296/25877313-2026-03-01
Das, S. K., Dutta, S., Pradhan, S., & Saikia, R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04314-8
“3) [54].”
Azuma, T. (2024) · Institutional Repositories DataBase (IRDB)
Luffman, N., Hu, B., Koblinski, J. E., Gewirtz, D. A., & Harada, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.13.718209 · Cited by 1
“As a result, senescent cells may acquire chemoresistance and fail to become sensitized to cell death, eventually recovering their proliferative capacity leading to tumor relapse 20,21 .”
Recent Advancements in Chemotherapy for Targeted Therapeutic Strategy
Agrawal, N., Dewangan, R., Siddiqui, M. A., Lanjhiyana, S. K., & Jaiswal, M. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814113126010011
Cheng, X., Chen, W., Hao, W., Guo, Y., Zhang, J., Song, C., He, Z., Wu, H., & Yao, D. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118680
Simmons, C. E., Khan, O. F., Brezden‐Masley, C., Cescon, D. W., Joy, A. A., LeVasseur, N., Jerzak, K. J., Gelmon, K. A., Sehdev, S. R., Chia, S., et al. (2026) · Current Oncology · doi:10.3390/curroncol33050243 · Cited by 1
“Sacituzumab govitecan, an ADC targeting trophoblastic cell-surface antigen 2 (TROP-2), a cell-surface glycoprotein overexpressed in ~80% of TNBC tumours, with a topoisomerase I payload, has already demonstrated survival benefit in later-line disease [128–131].”
Trop2 immunoPET/CT in clinical practice: facts and challenges
Deng, A., Jia, W., Huang, G., Liu, J., & Wei, W. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104684
B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer
Kiełbik, A., Bahlinger, V., Schürch, C. M., Barcena, M. L., Vakhrusheva, O., Thomas, A., Tsaur, I., Heitmann, J. S., Salih, H., & Hagelstein, I. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s577364
“49 To date, no bsAbs, including those that are approved for other solid tumors, are being evaluated for treatment of PeCa, underscoring a critical gap in therapeutic development for this rare disease.”
Antibody-Drug Conjugates in Oncology: Mechanisms, Clinical Progress, and Future Directions
Zhu, Z., Wang, S., Hong, W., Zhong, Q., Wang, W., Wang, N., Bai, M., & Ji, Z. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.32
Oncofetal Biology: From Fundamental Mechanisms to Emerging Therapeutic Opportunities
Liu, Y., Niu, K., Kong, Q., & Gao, S. (2026) · MedComm – Oncology · doi:10.1002/mog2.70071 · Cited by 1
LncRNAs as regulators of chemoresistance and chemosensitivity in triple-negative breast cancer
Cáceres-Durán, M. Á., Rodrigues, A. C. L., de Azevedo, J. C., Alves, C. D., Calcagno, D. Q., & Borges, B. D. N. (2026) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2025-0242
Zañudo, J. G. T., Kurt, B. B., Frangieh, A., Barkell, A. M., Navarro, J., Ngo, L. D., Mohammed-Abreu, A., Prade, V. M., Bisha, I., Abhishek, S., et al. (2026) · medRxiv · doi:10.64898/2026.05.22.26353710
Self-citationTreatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials
Shen, Y., Jiao, X., Wen, Y., Peng, Z., Zhao, X., Liu, J., & Gao, Q. (2026) · Cancer Innovation · doi:10.1002/cai2.70065
“Similarly, TROP2‐directed ADCs such as sacituzumab govite-can have shown encouraging results in early‐phase studies involving patients with heavily pretreated endometrial cancer [113–115].”
Liu, C., Zhao, J., Cheng, Y., Chen, T., Guo, S., Yang, C., Niu, Z., Pan, Y., Xie, S., Li, M., et al. (2026) · Nanotechnology · doi:10.1088/1361-6528/ae7a7d · Cited by 1
“Recently, novel drugs targeting new therapeutic avenues have been validated and approved, including immune checkpoint inhibitors [14, 15], TROP2-targeted therapies (via antibody-drug conjugates) [16, 17], and PARP inhibitors [18, 19].”
Table S1 from The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
Tolaney, S. M., Cardillo, T. M., Chou, C.-C., Dornan, C., & Faris, M. (2026) · doi:10.1158/1078-0432.32712120
Self-citationTable S1 from The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors
Tolaney, S. M., Cardillo, T. M., Chou, C.-C., Dornan, C., & Faris, M. (2026) · doi:10.1158/1078-0432.32713267
Self-citationHao, Z., Villano, J. L., Arnold, S. M., & Anthony, L. B. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261458324
Pérez-Bermejo, M., Albalate, M. M., Murillo-Llorente, M. T., Pérez-Murillo, J., Legidos‐Garcia, M. E., Tomás‐Aguirre, F., Palau-Ferrè, A. M., Martínez-Peris, M., & Ventura, I. (2026) · Cancers · doi:10.3390/cancers18122005
“…comprised one randomized controlled trial (the phase III ASCENT [26,27]), two single-arm clinical trials (the phase I/II IMMU-132-01 basket trial [25] and the phase IIb EVER-132-001 trial in Chinese patients [45]), and six retrospective real-world cohorts from Italy, France, the United States,…”
InfluentialPerioperative management of dermatologic surgery patients on systemic cancer therapy
Trager, M. H., Gordon, E. R., Handfield, C., Kriplani, A., Smithy, J. W., Rossi, A., Lee, E., Nehal, K., & Connolly, K. L. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.06.126
Xu, Z., 丁林贤, Zhao, T., & Xu, Z. (2026) · Oncology Reviews · doi:10.3389/or.2026.1834466
Promotion of tumor cell senescence by the antibody–drug conjugate, sacituzumab govitecan
Chakraborty, E., Sinanian, M. M., Rahman, A., & Gewirtz, D. A. (2026) · Molecular Pharmacology · doi:10.1016/j.molpha.2026.100142 · Cited by 1
TROP2 Is Uniformly Expressed in Primary Prostate Cancer but Frequently Reduced in Recurrent Disease
Jeutner, J., Simon, R., Lennartz, M., Minner, S. J. P., Burandt, E., Gehrisch, F., Schraps, N., Kluth, M., Sauter, G., Plage, H., et al. (2026) · Cancers · doi:10.3390/cancers18142359
Toli, M. A., Sarafidis, M., Filis, P., Tzoras, E., Tsiknakis, N., Sifakis, E. G., Liatsou, Ε., Rassidakis, G., Bergh, J. C. S., Matikas, A., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05093-3
Chi, W. Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.19.745876
“The clinical validation of TROP2 antibody drug conjugates has established TROP2 as an oncology target of high clinical relevance [7, 8].”
Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates
Ma, X., Li, B., Ma, Y., & Lau, J. Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115314
Wang, Q., Huang, Q., Ou, H., Huang, T., He, Y., & Li, P. (2026) · Drug Development Research · doi:10.1002/ddr.70377
“For example, sacituzumab govitecan a TROP2 antibody‐drug conjugate effectively increases the median progression‐free survival of TNBC patients from 1.7 to 5.6 months compared to the single‐agent chemotherapy (Bardia et al. 2019).”
InfluentialLiu, S., Zeng, B., Chen, D., Zhang, R., Wang, Z., Liu, Y., Tang, P., Xiao, J., & He, J. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112875
Scotté, F., Lustberg, M. B., Aapro, M., Abid, F. B., Bosnjak, S. M., Ruhlmann, C. H. B., Klastersky, J., Mayeur, D., Rugo, H. S., & Cooksley, T. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117054
Self-citationKhurram, I., Manzoor, H., Ghani, M. U., Alzahrani, A. R., Rehman, Z. U., Imran, M., Khan, A., & Khan, M. U. (2026) · Scientific Reports · doi:10.1038/s41598-026-70963-y
Safety management of anti TROP2 ADCs in patients with breast cancer
Malagutti, B., Malvezzi, G., & Zagami, P. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001276
Wang, Z., Lyu, S., Mu, Y., & Pei, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1948167
“In patients with metastatic TNBC who had received prior therapy, SG conferred substantial clinical benefit, as evidenced by prolonged response duration, extended progression-free survival (PFS), and improved overall survival (OS) (15).”
Fantozzi, P. J., Sonis, S. T., Botticelli, A., Scagnoli, S., Verrico, M., Bianchini, G., Bonomo, M. V., Bonadonna, C., Casagrande, M., Borghetti, L., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag359
“33,34 Similar OM rates have been reported with T-DXd, ranging from 7.8% to 15.6% 35–37 , although another study reported a higher prevalence of 35.3%, with 2.0% of patients developing grade ≥ 3 OM.”
InfluentialAntibody-Drug Conjugate-Associated Oral Toxicities
Kur, K., Elad, S., Greenhouse, I., Beaumont, S., & Yarom, N. (2026) · Oral · doi:10.3390/oral6050125
Koumprentziotis, I., Cawley, A., Ewig, E., Gérard, A. O., Labat, M., Kamińska‐Winciorek, G., Kubeczko, M., Rapparini, L., Starace, M., Grafanaki, K., et al. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-08090-5
Glycosylation in Quality and Safety of Therapeutic Proteins
Matsumoto, Y., Kim, J., McKenna, K. R., Biel, T. G., Kirshner, S., Falkowski, V. M., & Ju, T. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100163
Lin, Y., Dang, Y., Li, X., Li, T., Yang, J., & Ling, X. (2026) · Case Reports in Oncology · doi:10.1159/cro/abzag057
Lauro, V. D., Sacco, P. C., Palma, V., von Arx, C., Buono, G., Caputo, R., Piezzo, M., Cocco, S., Vitale, E., Santoni, M., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2743869
Milani, M., Riccetelli, F., Strina, C., Alberio, M., Cervoni, V., Ziglioli, N., Caffi, D., Ferré, F., Maïo, M. D., Pravettoni, G., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag394
Dual HER2 and TROP2 Antibody–Drug Conjugates Overcome Tumor Heterogeneity in Breast CancerPreprint
Bertucci, F., Guillé, A., Finetti, P., Cohendet, A., Cabaud, O., Lumet, G., Castellano, R., Mescam, L., Gonçalvès, A., Denicolaï, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11269990/v1
Accurate assessment of surgical HER2-low status based on core needle biopsy data of breast cancer
Li, W., Chen, Z., Li, J., Ding, T., 雷海科, Chen, R., & Li, J. (2026) · Diagnostic and Prognostic Research · doi:10.1186/s41512-026-00241-y
Zhao, Y., Ma, X., Liu, X., & Yan, L. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04964-z
“SG employs a pH-sensitive cleavable linker to com - bine the humanized anti-TROP2 monoclonal antibody hRS7IgG1k with the payload TOP1 inhibitor SN-38 [51 ].”
Fang, L., Song, J., Wang, X., Wang, F., & Zhu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1978134
BindingDB (2022) · UC San Diego · doi:10.7270/q2k0780v
Feng, H., Padala, C., & Liu, B. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168515
TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome
Stanbery, L., Craig, D., Rager, L. E., Morand, S. M., Nemunaitis, A., Nemunaitis, N., Nejedlik, J., Choi, J., Phinney, R. C., & Nemunaitis, J. J. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2756200
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.